Retrospective Study Shows the Safety & Efficacy of High Flow Therapy Compared to CPAP

EXETER, NH, November 24, 2014 – Vapotherm, Inc., a developer and manufacturer of advanced respiratory care technology, today announced the results of a recent study showing the safety and efficacy of High Flow Therapy in a large population of very low birth weight babies.

Safety and Long Term Outcomes with High Flow Nasal Cannula Therapy in Neonatology: A Large Retrospective Cohort Study, McQueen, M. et. al., published in the Journal of Pulmonary and Respiratory Medicine, compares pulmonary outcomes in very low birth weight babies from five centers who use Vapotherm High Flow Therapy as their primary mode of non-invasive ventilatory support to the pulmonary outcomes from the Vermont Oxford Network (VON) database. The study compares the rates of pneumothorax, infection, and long-term oxygen use (an indicator of bronchopulmoanry dysplasia) in the two populations.

“This study delivers the critical clinical message that Vapotherm High Flow Therapy is a safe form of respiratory support for even the smallest neonates,” said Joe Army, President and CEO of Vapotherm. “Furthermore, it is another large cohort study that shows Vapotherm High Flow Therapy is a suitable alternative to CPAP in the NICU.”

To read the entire study, visit:

Vapotherm, Inc. is a privately held developer and manufacturer of advanced respiratory care technology based in Exeter, New Hampshire. The company develops innovative, comfortable, noninvasive technologies for respiratory support of patients with chronic or acute breathing disorders. Over 1,000,000 patients have been treated with Vapotherm High Flow Therapy. For more information, visit

Contact: Lise Halpern, VP Marketing & Clinicals (603) 658-0011

2017-04-07T01:40:04-04:00Nov 24|Vapotherm Company News|
Go to Top